Impression life with pulmonary hypertension: clinically relevant characteristics and quality of life among patients in Gansu, China
- PMID: 38676370
- PMCID: PMC11055475
- DOI: 10.1177/17534666241246428
Impression life with pulmonary hypertension: clinically relevant characteristics and quality of life among patients in Gansu, China
Abstract
Background: The adverse effects of pulmonary arterial hypertension (PAH) on physical, emotional, and health-related quality of life (HRQoL) remain primarily unrecognized, especially in resource-limited settings.
Objectives: This study aims to characterize the HRQoL of patients with PAH in this area and also identify the potential role of clinically relevant characteristics, including the 6-min walk distance test (6MWD), WHO-Functional Classification (WHO-FC), and mental health in the occurrence of lowering quality of life.
Design: This was a cross-sectional observational study.
Methods: Inpatients with PAH were chosen from a tertiary hospital located in Gansu province, China. All participants were interviewed face-by-face by using questionnaires, including items from the 36-Item Short Form Health Survey (SF-36), the self-rating anxiety scale, and the self-rating depression scale. Data on demographic and clinically relevant characteristics, including WHO-FC and 6MWD, were also collected by tracing medical recorders. Multiple linear regression analysis was used to determine the association between demographic, clinically relevant characteristics data, and physical component summary (PCS) or mental component summary (MCS) in SF-36.
Results: Of the 152 participants, SF-36 differed significantly from Chinese norms in all eight domains, with role-physical (21.55 ± 9.87) less than one-third of the norm (88.79 ± 28.49). Multiple linear regression results showed that the factors with the greatest impact on PCS were anxiety scores (β = -0.22, p = 0.001), followed by WHO-FC (β = -0.16, p = 0.014) and 6MWD (β = 0.15, p = 0.036). The factors with the greatest impact on MCS were WHO-FC (β = -0.30, p < 0.001), followed by anxiety (β = -0.23, p = 0.001) and depression scores (β = -0.16, p = 0.013).
Conclusion: HRQoL was substantially reduced among PAH patients in the resource-limited area, mainly the physiological functions. WHO-FC and anxiety scores were independently associated with both PCS and MCS in SF-36. Clinicians should make reasonable rehabilitation programs and plans for patients according to their cardiac function grade and the severity of clinical symptoms. In addition, psychological interventions should also be taken, especially for those with anxiety symptoms, so as to improve their HRQoL.
Keywords: 6MWD; HRQoL; MCS; PAH; PCS; WHO-FC.
Conflict of interest statement
The authors declare that there is no conflict of interest.
Figures


Similar articles
-
Emotional symptoms and quality of life in patients with pulmonary arterial hypertension.J Heart Lung Transplant. 2014 Aug;33(8):800-8. doi: 10.1016/j.healun.2014.04.003. Epub 2014 Apr 19. J Heart Lung Transplant. 2014. PMID: 24854567
-
Impact of psychological factors on the health-related quality of life of patients treated for pulmonary arterial hypertension.J Psychosom Res. 2018 Feb;105:45-51. doi: 10.1016/j.jpsychores.2017.12.003. Epub 2017 Dec 6. J Psychosom Res. 2018. PMID: 29332633
-
Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial.Chest. 2017 Jan;151(1):106-118. doi: 10.1016/j.chest.2016.08.1473. Epub 2016 Sep 23. Chest. 2017. PMID: 27671974 Clinical Trial.
-
Selection of patient-reported outcome measures in pulmonary arterial hypertension clinical trials: a systematic review, meta-analysis and health-related quality of life framework.Eur Respir Rev. 2025 May 14;34(176):250006. doi: 10.1183/16000617.0006-2025. Print 2025 Apr. Eur Respir Rev. 2025. PMID: 40368429 Free PMC article.
-
Phosphodiesterase 5 inhibitors for pulmonary hypertension.Cochrane Database Syst Rev. 2019 Jan 31;1(1):CD012621. doi: 10.1002/14651858.CD012621.pub2. Cochrane Database Syst Rev. 2019. PMID: 30701543 Free PMC article.
Cited by
-
Trends in pulmonary arterial hypertension: insights from Global Burden of Disease 1990-2021.BMJ Open. 2025 Mar 18;15(3):e095348. doi: 10.1136/bmjopen-2024-095348. BMJ Open. 2025. PMID: 40107705 Free PMC article.
References
-
- Galiè N, Humbert M, Vachiery JL, et al.. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46: 903–975. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical